STAT+

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Pfizer pulling a sickle cell pill, Moderna getting scolded, and more

Biotech Elaine Chen

STAT Plus: AbbVie Parkinson’s drug helps improve symptoms in late-stage study

Biotech Allison DeAngelis

STAT Plus: ARCH Venture Partners raises $3 billion for a new biotech fund

Adam's Take Adam Feuerstein

STAT Plus: Why Biohaven will test the FDA’s regulatory limits  

Adam's Take Adam Feuerstein

STAT Plus: Gene therapy for sickle cell disease remains a tough business model — and may never work

Health tech Mario Aguilar

STAT Plus: Sleep apnea alert on Apple Watch: What does it mean, and how does it work?

Biotech Adam Feuerstein and Jason Mast

STAT Plus: Pfizer pulls sickle cell treatment Oxbryta off global markets

Pharmalot Ed Silverman

STAT Plus: Moderna is scolded by a U.K. trade group for offering kids $2,000 to participate in a Covid trial

Biotech Andrew Joseph

STAT Plus: Celldex drug reduces chronic hive activity, but patient discontinuations raise questions

Exclusive John Wilkerson and Rachel Cohrs Zhang

STAT Plus: Generic drug lobby taps former BIO exec as new CEO

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Sanders and Novo Nordisk CEO sparring, Roche refocusing, and more

Matt's Take Matthew Herper

STAT Plus: Can Anne Wojcicki save 23andMe?

Exclusive Jonathan Wosen

STAT Plus: The little-known Chinese biotech whose cancer drug beat Keytruda has global ambitions

Biotech Jonathan Wosen and Allison DeAngelis

STAT Plus: Amgen scores late-stage trial success for eczema and myasthenia gravis treatments, but faces stiff competition

Pharmalot Ed Silverman

STAT Plus: Baltimore claims Biogen ‘bribed’ PBMs to favor its pricey MS drug over generics

Biotech Stella Tannenbaum — The Boston Globe

STAT Plus: Bluebird Bio is laying off 25% of its workers to cut costs

Politics Rachel Cohrs Zhang and Elaine Chen

STAT Plus: Sanders says PBMs won’t penalize Novo for cutting Ozempic, Wegovy prices

Biotech Matthew Herper

STAT Plus: Amid push to redefine itself, Sanofi names new chief scientific officer

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Regeneron biosimilar fight, a ‘positive surprise’ for Biogen lupus drug, and more

Biotech Adam Feuerstein

STAT Plus: Regeneron’s Eylea biosimilar fight heats up

Biotech Brittany Trang

STAT Plus: Novartis strikes AI drug development deal with Generate:Biomedicines

Politics Leslie Walker and Dan Gorenstein

STAT Plus: The U.S. has relied on cheap, effective generic drugs for 40 years. Now that promise is under threat

Biotech Adam Feuerstein

STAT Plus: Risky bet by Biogen and UCB on systemic lupus drug appears to pay off, data show

Exclusive Lev Facher and Mario Aguilar

STAT Plus: Lawmakers push to let telehealth providers keep prescribing stimulants and addiction treatment

Health Care Inc. Bob Herman

STAT Plus: Will prescription drugs get prior authorization reform?

Health tech Casey Ross

STAT Plus: Electronic health records giant Epic Systems sued over alleged monopolistic practices

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a ‘Bust Big Pharma’ bus tour, few smoking-cessation drugs, and more

Politics John Wilkerson

STAT Plus: Wegovy is among drugs set to be targeted in the next round of Medicare price negotiations, researchers say

Pharma Rachel Cohrs Zhang

STAT Plus: PhRMA scores a small win in legal challenge to Medicare’s drug price negotiation